Most peptides in a research catalogue trace back to a Western pharmaceutical lab or a university spin-out. Semax does not. It was born inside a Soviet-era research institute in Moscow, built deliberately from a piece of a stress hormone, and for decades almost every study written about it appeared in Russian. That origin story shapes what we know, and what we still do not know, about the compound.
From ACTH to a shorter fragment
Semax begins with adrenocorticotropic hormone, or ACTH, a 39-amino-acid hormone the pituitary releases to switch on the adrenal glands. By the mid-twentieth century, researchers had noticed something odd about ACTH: certain short fragments of the molecule seemed to affect the brain and behaviour without triggering the hormonal cascade that the full peptide sets off. The stretch that drew the most attention was ACTH(4–10) — the fourth through tenth amino acids of the parent hormone.
That fragment carried neurotropic activity in early animal work, but it had a fatal practical flaw. In the body it broke down almost immediately, chewed up by enzymes before it could do much of anything. A compound that vanishes in minutes is difficult to study and useless as a drug. The problem was not the idea; it was the durability.
Who developed Semax
The answer to that problem came from the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow. Working there in the 1980s, a team associated with the peptide chemist Nikolai Myasoedov, together with physiologist Ivan Ashmarin, set out to build a more stable version of the active ACTH fragment. (Sources vary on the exact founding date and on the spelling of collaborators’ names, so treat specific years with some caution; the compound was first described in the scientific literature around 1991.)
Their solution was elegant. They took the core active piece of the fragment — ACTH(4–7), the sequence Met-Glu-His-Phe — and attached a short tail of three amino acids to the end: Pro-Gly-Pro. The finished heptapeptide reads Met-Glu-His-Phe-Pro-Gly-Pro. That Pro-Gly-Pro tail is the whole trick. Proline-rich sequences resist the proteases that shred ordinary peptides, so the tail acts as armour, letting the active head survive long enough to be studied. Semax is therefore best understood not as a natural fragment but as an engineered analog of ACTH(4–10), designed for stability the original never had.
From lab compound to Russian medicine
Through the 1990s and 2000s, Semax was studied heavily inside Russia, largely in the contexts of stroke, cognitive impairment, and the nervous system’s response to injury. Russian investigators reported effects on neuroprotection and on brain-derived neurotrophic factor, though the precise mechanism of action has never been fully pinned down and is still described in the literature as unknown.
What is documented is the regulatory path. Semax was registered as a medicine in Russia in the mid-1990s and later added to the country’s List of Vital and Essential Medicines, an official register of drugs the state considers important, in a revision dated December 2011. That status is specific to Russia. Semax has not been approved by the United States Food and Drug Administration, the European Medicines Agency, or comparable regulators in most other countries, and it is not an approved medicine in New Zealand.
What the record actually supports
The honest summary is that Semax has an unusually long research history for a peptide of its obscurity, but a lopsided one. The bulk of the literature is Russian, a large share of it is preclinical or early-stage, and much of the clinical work has not been replicated in the large, independent, international trials that Western regulators expect. Interesting signals exist in the published record. Definitive, widely accepted conclusions do not.
That gap between an intriguing history and a thin global evidence base is exactly why Semax remains a subject of active laboratory research rather than a settled therapy. It is a compound with a clear origin, a clever design, and a long list of open questions.
→ Semax Research Guide · COA available Semax range
Research use only. Semax is supplied by Vero Labs strictly as a research compound for laboratory and scientific investigation. It is not intended for human or animal use, and nothing here is medical advice or a description of results in people. Every batch is independently third-party lab-tested for identity and purity, with a published Certificate of Analysis available for the material you receive.